By
The global prosthetics and orthopaedic support market is expected to continue expanding steadily in the coming years, according to new insights shared by Embla Medical. Company leadership estimates that the overall market for prosthetic technologies and related rehabilitation solutions is growing at between 6% and 8% per year, reflecting rising demand for mobility solutions worldwide.
The outlook was presented during a recent Life Science Day event in Gothenburg, where Embla Medical executives discussed industry trends, company performance and long-term growth opportunities within the global orthotics and prosthetics sector.
A Growing Global Market for Prosthetic Solutions
Embla Medical—previously known as Össur—develops prosthetic limbs, bracing systems and rehabilitation solutions used by patients recovering from injury, limb loss and musculoskeletal conditions.
According to the company’s investor presentation, the global market for prosthetics and related technologies is currently valued at around $2 billion, with annual growth expected to remain within the 6–8% range over the coming years.
This steady growth reflects a combination of factors including:
- increasing rates of diabetes and vascular disease
- rising demand for rehabilitation technologies
- improved access to prosthetic care in emerging markets
- continued innovation in prosthetic design and materials
Company Targets Continued Revenue Growth
Embla Medical has set ambitious financial targets that align with these industry trends. The company aims to achieve annual sales growth of 7–10%, driven by both organic expansion and strategic acquisitions.
Management expects organic growth to contribute approximately 5–7% per year, with acquisitions adding a further 2–3% to overall expansion. The company is also targeting improvements in profitability through operational efficiency and portfolio development.
In 2025, Embla Medical reported revenue of approximately $929 million, with an operating profit of $125 million, representing an operating margin of 13.5%. The company’s adjusted EBITDA margin reached around 20%.
For 2026, Embla Medical expects organic sales growth in the range of 5–8%, while aiming to increase its adjusted EBITDA margin to 20–22%.
Strong Recurring Revenue Model
One of the key characteristics of the prosthetics industry is the significant level of recurring revenue. Embla Medical estimates that 70–80% of its income comes from repeat purchases, reflecting the ongoing clinical needs of prosthetic users.
Prosthetic components, liners, sockets and other devices often require replacement or upgrades over time, creating a stable long-term market for manufacturers and suppliers.
Emerging Markets Represent the Largest Opportunity
Despite strong growth in developed healthcare systems, emerging markets may represent the greatest opportunity for future expansion.
Embla Medical notes that only around 10% of its revenue currently comes from emerging markets, even though these regions are home to approximately 80% of the world’s amputees.
Improving access to rehabilitation services, prosthetic technology and trained clinicians in these regions could dramatically expand the global market for prosthetic solutions.
Implications for the O&P Industry
The continued growth forecast for prosthetics and orthotic technologies highlights the increasing importance of rehabilitation services worldwide. Rising chronic disease rates, ageing populations and advances in prosthetic engineering are all contributing to sustained demand for mobility solutions.
For clinicians, manufacturers and suppliers working across regions such as the Middle East, Africa and Asia, these trends suggest that the prosthetics sector will remain a dynamic and expanding part of the global medical technology industry.
As rehabilitation services continue to evolve, the ability to deliver advanced prosthetic technologies alongside accessible clinical care will be critical in meeting the mobility needs of millions of people living with limb loss around the world.
